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Abstract
Immediately after the annual scientific meeting of the American Society of Hematology (ASH), a
select group of clinical and laboratory investigators in myeloproliferative neoplasms (MPN) is
summoned to a post-ASH conference on chronic myeloid leukemia and the BCR-ABL1-negative
MPN. The 6th such meeting occurred on 13th–14th December 2011, in La Jolla, California, USA,
under the direction of its founder, Dr. Tariq Mughal. The current document is the first of two
reports on this post-ASH event and summarizes the most recent preclinical and clinical advances
in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
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Introduction
Since the discovery of the JAK2-V617F mutation in 2005, the myeloproliferative neoplasms
(MPN) have been the objective of multiple gene discovery efforts. Exome and whole-
genome sequencing in MPN are currently underway. In the meantime, use of array-based
technologies and candidate gene sequencing have resulted in the identification of several
novel somatic mutations (Table I). Prominent amongst these are alterations that affect
epigenetic regulation of transcription, including mutations inTET2 (1, 2) and DNMT3A (3,
4) as well as the recent discovery of mutations and copy-number loss in multiple members
of the Polycomb Repressive Complex 2 (PRC2) (5–8). In the last year, much progress has
been made in determining the functional implications of these mutations in both normal
hematopoiesis and MPN pathogenesis. Currently, a great deal of effort has been placed on
understanding the hierarchy of these somatic mutations, the order of mutation acquisition,
and potential cooperativity of co-existing mutations in affecting the MPN phenotype. In
parallel with increased understanding of the pathophysiology of MPN from genetic studies,
recent therapeutic studies on the use of JAK inhibitors and pegylated-interferon alpha (PEG-
IFNα) have increased our pathogenetic insight in these diseases.
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Preclinical Advances in the Pathogenesis and Therapy of
Myeloproliferative Neoplasms
TET2 mutations
Somatic mutations in TET2 are now well-established as occurring in patients with all
myeloid malignancies including 7–16% of patients with polycythemia vera (PV), 4.4–11%
with essential thrombocythemia (ET), and 7.7–17% of patients with primary myelofibrosis
(PMF)(1, 2, 9) (Table I). When Delhommeau and colleagues first described TET2 mutations
in MPN, evidence for its importance in hematopoietic stem cell function was suggested by
xenograft studies (1). The authors noted that injection of JAK2V617F-positive CD34 cells
from MPN subjects with (n=2) or without TET2 mutations (n=3) into NOD-SCID mice
revealed a more efficient engraftment in the presence, as opposed to absence, of TET2
mutations. TET2 mutations could also be identified in the engrafted cells suggesting that the
mutation was present at the stem/progenitor cell level. Moreover, the resulting
hematopoiesis was skewed towards increased frequency of myeloid progenitors over
lymphoid progenitors.
In the last year, additional knowledge regarding the biological function of TET2 in
hematopoiesis has come from the study of mice with constitutive and conditional deletion of
Tet2. Five different Tet2 knockout mouse models were reported, all of which revealed the
consistent finding that Tet2 loss results in progressive expansion of the hematopoietic stem
cell compartment and eventual myeloproliferation in vivo, including splenomegaly,
monocytosis, and extramedullary hematopoiesis (10–13). In addition, Tet2+/− mice
displayed increased stem cell self-renewal and extramedullary hematopoiesis, suggesting
that Tet2 haploinsufficiency contributes to hematopoietic transformation in vivo (12).
In parallel with the above-stated biological studies, the biochemical function of TET2 has
been further clarified. TET2 is one of three memebers of Fe(II), α-ketoglutarate dependent
enzymes which serves to hydroxylate methylcytosine (14). Although not previously
appreciated in mammals, 5-hydroxymethylcytosine (5-hmc) may block binding of methyl-
binding proteins that are used to effect transcriptional silencing (15, 16). Studies in
embryonic stem cells have demonstrated enrichment of 5-hmc marks in CpG dinucleotides
near transcriptional start sites and within genes. 5-hmc may also lead to passive
demethylation because Dnmt1 is unable to recognize 5hmc and methylation marks become
lost through replication (17).
Recent studies have delineated a pathway where 5-hmc leads to active demethylation
through DNA repair pathways. DNA deaminases including activation-induced cytidine
deaminase (AID)/APoBEC are able to convert 5-hmc to 5-hydroxymethyl uracil (5-hmu).
This is followed by a base excision repair mechanism that uses the enzyme thymine DNA
glycosylase (TDG) or single-stranded monofunctional uracil DNA N-glycosylase SMUG1
(18, 19). Other studies have shown that TET enzymes may also affect conversion of 5-mc to
5-formylcytosine (5-fc) and 5-carboxylcytosine (5-cac); 5-cac can be directly recognized
and repaired by TDG (20).
Loss of TET enzyme activity results in increased methylation and reduced 5-hmc levels.
Patient samples with TET2 mutations display lower global 5-hmc compared to their wild-
type counterparts (21). Although defects in 5-hmc were also demonstrated in primary
hematopoietic tissues from Tet2 knockout mice, compared to controls in several of the Tet2
knockout models, current work is focused on identifying targets of aberrant DNA
methylation/hydroxymethylation, which may be important in regulating hematopoietic stem
cell homeostasis.
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Initial studies in MPN patients suggested the occurrence of TET2-mutant/JAK2-mutant and
TET2-mutant/JAK2-wildtype clones, but not TET2-wildtype/JAK2-mutant clones,
suggesting that TET2 mutations occur as a “pre-JAK2” event (1). However, subsequent
studies have noted the post-JAK2-V617F acquisition of TET2 mutations, refuting a
paradigm that mutations in TET2 represent the earliest genetic aberration in MPN (22).
Ongoing work examining cooperativity of Jak2-V617F mutations and Tet2 loss in vivo will
hopefully address the potential importance of the order of JAK2/TET2 mutation acquisition
on disease phenotype and HSC self-renewal in MPN (23).
DNMT3a mutations
DNMT3a mutations have also been described in MPN (3, 4). Although these mutations are
more frequent in AML and post-MPN AML, they also occur in chronic-phase MPN,
including in 10–15% of PMF patients and 5–7% of PV patients. Until recently, data from
murine studies suggested that Dnmt3a may be dispensable in HSCs (24). However, careful
characterization of the hematopoietic stem cell biology from Dnmt3a knockout mice in
serial transplantation experiments by Challen et al. has revealed that Dnmt3a loss results in a
striking expansion of HSCs (25). Despite the dramatic effects of Dnmt3a loss on HSC
number and frequency with serial transplantation, the effects of Dnmt3a loss on DNA
methylation and gene expression are quite perplexing. From in vivo studies of genome-wide
methylation status using HPLC-MS as well as bisulfite-sequencing of purified stem cell
populations, there appears to be very little correlation between Dnmt3a loss and DNA
methylation/gene expression at specific loci (25). Nonetheless, several genes which should
be repressed for normal HSC differentiation were found to be consistently upregulated and
hypomethylated with Dnmt3a loss including Runx1 and Gata3 (25). Although loss of
Dnmt3a in vivo still appears from this work to be insufficient for transformation or disease
phenotype, future work to address the combined effect of Dnmt3a loss with activating
alterations in Jak2 may be very enlightening.
Mutations in Polycomb group proteins
In addition to mutations affecting enzymes regulating DNA methylation and demethylation,
somatic mutations and copy-number alterations of genes regulating post-translational
modification of histones have been recurrently found in patients with MPN and MPN/MDS
overlap. These include recurrent mutations of EZH2, reported in 5–13% of patients with
PMF (26, 27) and somatic mutations and copy-number alterations of other members of the
Polycomb Repressive Complex 2 (PRC2).
Three independent groups have identified mutations in PRC2 core components SUZ12 and
EED or prominent deletions of PRC2 affiliated protein JARID2 (6–8). Although these
mutations are rare, occurring in 1–3% of patients with PMF, use of SNP array profiling by
two groups has identified more frequent copy number deletion among all PRC2 members as
well as deletions of PRC2 associated proteins Jarid2 and RBBP4 (7, 8). Recent clinical
correlative work by Guglielmelli et al. revealed association of EZH2 mutations with inferior
overall survival and leukemia-free survival in PMF (28). Likewise, Puda et al. suggested
that deletion of the genetic locus containing Jarid2 (6p) might be associated with leukemic
transformation (8).
In contrast to the accumulating genetic evidence for PRC2 loss-of-function alterations in
MPN pathogenesis and leukemic transformation, comparatively less is known about the
biological ramifications of these alterations. For instance, rigorous assessment of whether
such mutations actually affect the abundance and/or distribution of H3K27me3 in chromatin
has not yet been published, nor have the genetic targets of these alterations been clarified.
Murine models with conditional deletion of Ezh2 have been described (29). The myeloid
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phenotype of Mx1-Cre/Ezh2 homozygous null was not fully described in this particular
report. Further work to analyze the effects of PRC2 member deletion in vivo, alone and in
combination with other oncogenic alleles, will hopefully allow for a deeper understanding of
the contributions of these alterations to MPN and MDS pathogenesis.
Resistance to JAK targeted therapies
Given the recent FDA approval of ruxolitinib (INCB018424) for myelofibrosis and the
preclinical/clinical development of several additional JAK targeted therapeutics, a number
of groups have recently investigated potential mechanisms of resistance to ATP-competitive
JAK targeted therapies in in vitro mutagenesis paradigms. An initially published report by
Hornakova et al. identified a number of spontaneously occurring mutations in the
pseudokinase/kinase domains of JAK1, as well as JAK2, which result in both constitutive
JAK-STAT activation as well as resistance to JAK targeted therapies (30). This study
utilized a system of BaF3 cells transduced with a mutated IL-9Rα to first identify
spontaneously occurring mutations in JAK1 that result in autonomous cytokine-independent
growth. This BaF3 cell line initially fails to grow in response to IL-9 but after prolonged
culture eventually acquires responsiveness to IL-9 followed by acquisition of cytokine-
independent growth. Prior characterization of these cells identified that spontaneously
occurring mutations in endogenous JAK1 in addition to overexpression of JAK1 is
responsible for this cytokine-independent transformation (31). Hornakova et al. then utilized
this collection of BaF3 JAK1 mutant cells to examine their responsiveness to JAK inhibitor
I and ruxolitinib. The authors thus identified 2 mutations in JAK1 that resulted in
constitutive JAK-STAT pathway activation and conferred resistance to both JAK inhibitor I
and ruxolitinib: JAK1 F958 and JAK1 P960. Moreover, mutation at the homologous residue
in JAK2 (JAK2 Y931) conferred resistance to both JAK inhibitors and resulted in cytokine-
independent transformation of BaF3 cells (30).
Using a more systematic approach Deshpande et al. more recently identified additional point
mutations in JAK2 which confer resistance to a wider variety of JAK inhibitors (32). These
authors utilized a random mutagenesis screen in JAK2V617F cDNA followed by
introduction into BaF3 cells expressing the erythropoietin receptor and identified 5 non-
synonymous mutations in the drug-binding domain of JAK2 which resulted in resistance to
ruxolitinib as well as to AZD1480, TG101348, lestaurtinib (CEP-701), and CYT-387.
Interestingly one mutation (JAK2 Y931) matched that found by Hornakova et al. while the
other 4 were unique (G935, R938, I960, and E985). The authors also attempted to find the
homologous “gatekeeper” residue in JAK2 that matches the location of gatekeeper
mutations in BCR-ABL1, KIT, and EGFR. Surprisingly, mutations at this residue (JAK2
M929) conferred resistance to only ruxolitinib (32). Despite these intriguing biochemical
data, it is important to note that none of these genetic alterations have been identified in
primary MPN patient samples to date and it is not yet clear how resistance to JAK inhibitors
might be clinically defined. Recently, pre-clinical studies reported by Fiskus et al
demonstrated that co-treatment with heat shock protein (hsp) 90 inhibitor significantly
increased JAK inhibitor mediated depletion of JAK/STAT signaling in primary MPN cells
(33). Additionally, these studies showed that JAK inhibitor-resistant cultured human MPN
cells, isolated under the in vitro selection pressure of JAK inhibitor, were collaterally highly
sensitive to hsp90 inhibitor, thereby suggesting the in vivo testing of combined treatment
with hsp90 inhibitor to overcome resistance to JAK inhibitors.
HSC characterization in PMF
Recent advancements in the therapy of MPN patients have highlighted the need for
increased understanding and targeting of the transformed hematopoietic stem cells
underlying the MPN phenotype. While abnormalities in the mobilization, tracking, and
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localization of HSCs have long been identified as a hallmark of PMF [51,52], very little
functional characterization of the self-renewal and differentiation potential of HSCs from
PMF patients has been performed previously. At the 2011 ASH meeting, Wang et al.
presented an analysis of the engraftment and differentiation potential of HSCs from the
peripheral blood and spleen of PMF patients [53]. The authors first identified that larger
numbers of CD34+, CD34+CD38−, and CD34+CD90+ cells are present in the spleens of
PMF patients compared with the peripheral blood. Secondly, the authors performed a series
of xenografts of CD34+ cells from the spleen as well as peripheral blood of PMF patients
into NOD/SCID/IL2Rgnull (nonobese diabetic severe combined immunodeficient
interleukin-2 receptor gamma chain null) mice. Evaluation of the extent of human cell
engraftment in the marrow of these mice following transplantation revealed that engraftment
was superior in mice transplanted with splenic CD341 cells compared with peripheral blood
CD34+ cells. Moreover, splenic CD34+ cells appeared to be able to differentiate into
myeloid as well as CD19+ and CD3+ cells whereas peripheral blood CD34+ cells appeared
to be skewed towards myeloid differentiation. Collectively, these findings suggest that HSCs
present in different compartments of PMF patients vary in their differentiation and
engraftment potential. Further comparative analysis of the HSCs of PMF patients may reveal
important findings regarding the hierarchy of hematopoietic stem progenitor cells in MPN
patients as well as influences on the microenvironment and niche on HSC differentiation and
homing.
Role of inflammation in MPN pathogenesis
Inflammatory cytokines are markedly elevated in the sera of patients with MF and have been
shown to be downregulated by some, but not other, JAK inhibitors (33, 34). Recent work by
Tefferi et al. (35) and Pardanani et al. (36) have identified that serum cytokine profiling may
additionally be utilized to predict outcome in patients with PMF and may also be useful in
determining response to pomalidomide. In a seminal study, Tefferi et al. utilized a multiplex
bead-based Luminex assay to profile the levels of a large number of serum cytokines in the
sera of 127 patients with PMF (35). Careful clinical correlative work identified that
elevations in 5 cytokines (IL-8, IL-2R, IL-12, IL-15, and IP-10) predicted for significantly
worsened overall survival, independent of additionally clinically utilized variables in the
revised Dynamic International Prognostic Scoring System. Additionally, leukemia-free
survival was predicted by IL-8. An additional study from the same authors identified that
elevations of several of these cytokines (IL-8 and IL-2R) are also inversely correlated with
efficacy of pomalidomide therapy in treating anemia in PMF patients (36). Future work to
integrate serum cytokine levels, clinical variables, and molecular genetic abnormalities in
MPN patients may prove to be very enlightening in understanding MPN pathogenesis and
disease course.
Critical role of STAT5 in MPN pathogenesis
Increased laboratory and clinical investigations on the efficacy of JAK2 targeted therapies in
patients with MPN has continued to show that JAK2 inhibitor therapies as currently
administered are not able to eliminate the disease initiating clone in MPN patients (37) and
in many cases may not effectively reduce allele burden (34, 38). This has led to ongoing
interest in understanding the role of signaling events downstream of activated JAK2 in
MPN.
JAK2V617F activates multiple signaling pathways including STAT5, STAT3, Erk/MAP
kinase, and PI3 kinase/Akt. Recently, Yan et al. have demonstrated, using a Jak2V617F
knock-in mouse model, that STAT5 is a critical mediator in vivo for development of the
MPN phenotype (39). This was demonstrated genetically through crossing Jak2V617F knock-
in mice to mice carrying homozygous conditional null mutations in the Stat5ab gene locus.
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Deletion of Stat5 completely abrogated the MPN phenotype including splenomegaly,
erythrocytosis, and the increase in stem/progenitor compartment seen with Jak2V617F
expression in the presence of STAT5. In contrast, use of a dominant-negative form of
STAT3 or inhibitors of ERK or PI3K did not appear to affect the MPN phenotype induced
by conditional Jak2V617F expression in mice (39). Similar findings were reported in a
retroviral model of Jak2V617F -induced MPN, where deletion of Stat5 completely reversed
the polycythemia phenotype, but did not prevent the development of myelofibrosis (new ref:
Walz et al Blood 2012, epub 2012-01-2012). These data suggest that signaling from JAK2
to STAT5 may be critical for hematopoietic transformation in MPN and targeting STAT5
may be therapeutically useful.
The phenotypic diversity displayed by JAK2-V617F remains an enigma. One prevailing
hypothesis considers differential recruitment of signaling pathways downstream of JAK2 in
patients with PV versus ET. Consistent with this hypothesis, Chen et al. recently showed
that JAK2-mutated patients with ET preferentially activate STAT1, compared to patients
with PV (40). This finding came from careful gene expression analysis in individual
colonies from the blood of patients with PV and ET. The authors also showed that over-
expression of STAT1 in normal CD34+ cells promoted megakaryocytic development and a
phenotype akin to ET.
Clinical Advances in the Prognostication and Therapy of Patients with
Myeloproliferative Neoplasms
New prognostic tools
In parallel with the interest in understanding the potential utility of genetic and serological
factors to predict outcome in MPN patients, a number of advances in utilizing conventional
clinical parameters to predict outcome were discussed at the ASH meeting and post-ASH
symposium. The Dynamic International Prognostic Scoring System (DIPSS) score is
currently the most widely utilized scoring system to predict outcome at time of diagnosis in
PMF patients and includes age > 65 years, hemoglobin < 10g/dL, leukocytes greater than
25×109/L, circulating blasts ≥ 1%, and constitutional symptoms (41). In early 2011, the
International Working Group for MPN Research and Treatment (IWG-MRT) developed a
clinical prognostic algorithm incorporating karyotype, platelet count, and transfusion status
to the DIPPS score to allow for outcome prediction at any time point in the clinical care of
MF patients (42). More recently, Tefferi et al. performed a study of 884 PMF patients and
identified that a smaller list of the DIPSS-plus score items can be utilized to more simply
predict two-year predicted mortality in PMF patients (43). A greater than 80% 2-year
mortality in PMF is predicted by the presence of a monosomal karyotype (defined as =2
autosomal monosomies or a single autosomal monosomy associated with at least one
structural abnormality), inv(3) or inv(17)q abnormalities, or any 2 of the following: PB blast
> 9%, WBC ≥ 40 × 109/L, or other unfavorable karyotype. The simplicity of this predictive
algorithm may hopefully allow for improved risk stratification and management of PMF
patients.
In addition to the studies above in PMF, the IWG-MRT has also recently performed a large
international retrospective study of the natural history of PV including only patients
diagnosed with PV using 2008 WHO diagnostic criteria. This study of 1,430 PV patients
was presented at the 2011 ASH meeting and revealed that, with mature follow-up data,
patients with PV appear to have a shortened lifespan compared with sex- and age-matched
controls (44). Multivariate analysis identified advanced age, leukocytosis, venous
thrombosis history and abnormal karyotype as significant (p<0.01) risk factors for overall
survival in PV.
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Updates on JAK inhibitors
Since the initial publications of the phase I/II trial of ruxolitinib (33) and the phase I trial of
TG101348 in patients with MF (45), knowledge about the role, schedule, and potential
toxicities of a variety of JAK inhibitors continues to accumulate from clinical trials of these
agents. At the 2011 ASH annual meeting, updates on 2 controlled trials of ruxolitinib in
myelofibrosis (the COMFORT-I and -II trials) were presented (46, 47). COMFORT-I, a
double-blind placebo controlled trial of ruxolitinib in MF, includes a total of 309 pts and
clearly shows a benefit of ruxolitinib over placebo in reducing spleen volume and improving
the Total Symptom Score at 24 weeks (47). Less clear are the effects of ruxolitinib on
survival in MF from this study although this also appears potentially promising as 13
ruxolitinib-treated versus 24 placebo-treated patients have died so far (median follow-up of
52 and 51 weeks respectively), representing a hazard ratio (95% CI) of 0.499 (0.254, 0.98)
(p=0.0395). A more extended follow-up should address the effects of ruxolitinib on survival
over placebo.
In addition to an update on COMFORT-I, preliminary results from COMFORT-II, a
randomized open-label phase III trial of ruxolitinib compared with best available therapy in
MF, was presented at the 2011 ASH meeting (46). Data from 219 patients randomized in a
2:1 fashion was presented and revealed a clear efficacy in ruxolitinib at reducing spleen size
and improving symptoms and overall QoL, according to EORTC and FACT-LYMP scale.
Currently, however, there is no evidence of a survival benefit; moreover, clear effects of
ruxolitinib on JAK2V617F allele burden are not yet clear from these trials.
In an attempt to understand the effects of ruxolitinib on the natural history and survival of
PMF while the COMFORT-I/II studies are ongoing, several investigators presented abstracts
comparing the extended outcome of PMF patients from the phase I/II trial to historical
controls (48–50). The resulting data regarding the effects of ruxolitinib on survival in PMF
appear conflicting from these reports however. Nonetheless, it is clear from these reports
that there are important potential adverse effects from ruxolitinib to be aware of such as
worsening of cytopenias (including potentially irreversible thrombocytopenia) and serious
withdrawal effects (rapid splenic enlargement and acute hemodynamic compensation) (48).
Further clinical use of ruxolitinib and results from phase III trials will hopefully clarify the
impact of this compound on the natural history of MF and the safety of this drug.
In addition to updated reports on ruxolitinib, clinical reports of several additional JAK
inhibitors in MF were presented at the 2011 ASH meeting including a phase II study of
pacritinib (SB1518) (51), a phase I/II study of SAR302503 (TG101348) (52), and a phase I/
II study of CYT387 (53). Early data from these trials suggest that there may be a role for
each of these JAK inhibitors in MF treatment as they may safely improve spleen size and
constitutional symptoms at doses that induce minimal myelosuppression. Amongst these 3
reports, data from the phase I/II study of SAR302503 suggests that the compound may
actually confer a durable decrease in JAK2V617F allele burden relative to the starting
JAK2V617F allele burden (52). Data from the phase I/II study of CYT387 continues to
suggest a unique role for this drug in MF as it appears to result in significant improvements
in anemia (53). This observation is of considerable interest and the potential underlying
molecular mechanism speculative. The most common grade 3–4 toxicity of CYT387 is
thrombocytopenia (occurring in 16% of subjects). Further follow-up of all of these studies
will continue to inform our understanding of the potential role, specific adverse effects, and
dosing schedules of the increasing variety of JAK inhibitor therapies.
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Interferon-alpha in the treatment of MPN patients
In addition to the burgeoning use of JAK2 targeted therapies in MPN patients, a number of
clinical studies updating results on the use of pegylated interferon alpha-2a (peg-IFN-α2a)
were presented at the ASH 2011 meeting. Updated data on a phase II trial of peg-IFN-a2a in
40 patients with high-risk PV and ET from Turlure et al. continue to reveal the efficacy of
peg-IFN-α2a in producing durable complete hematologic and molecular remissions in these
patients (54). In this study, 94% of patients remained with a sustained hematological
response, including 82% with complete remission, after 6.4 years median follow-up.
Moreover, 29% of patients were able to stop peg-IFNα-2a and sustained a hematological
response without further cytoreductive therapy after a median observation time of more than
28 months (with one patient up to 64 months). 28% of the patients in this study achieved a
complete molecular response, as measured by JAK2-V617F allele burden in granulocytes.
Kiladjian et al. studied several patients on PEG-IFN-α2a (55) and found persistence of
TET2 mutations despite eradication of JAK2 mutations in patients with JAK2/TET2
mutations. Quintas-Cardama et al. similarly performed molecular studies in high-risk PV
and ET patients undergoing treatment with peg-IFN-a2a (56) and demonstrated that patients
who failed to achieve a complete molecular remission were statistically more likely to have
a mutation outside of JAK2 (e.g. TET2, DNMT3A) during the course of therapy. The
findings from the 2 studies above suggest a possible influence of additional mutations
outside of JAK2 on resistance to PEG-IFN-α-2a therapy. It will be interesting to learn if
mutations in genes other than JAK2 are also differentially affected by JAK inhibitor therapy.
Pomalidomide, HDAC inhibitors, and allogeneic stem cell transplantation
Currently a phase III trial of the investigational immunomodulatory drug pomalidomide is
underway as a single agent in the therapy of patients with MF based on data from phase II
randomized trials revealing that the pomalidomide at 0.5mg to 2mg per day is active in MF
and effective at improving anemia (57). Longer-term follow-up data from patients on phase
I and phase II trials were presented at the 2011 ASH meeting and revealed that responses to
pomlidomide most commonly occur at a median of 2.3 months after the start of therapy and
are durable for a median of 16.5 months (range 2–40 months) (58). An additional phase II
trial using a low (0.5mg) continuous daily oral dose of pomalidomide revealed that although
a portion of transfusion-dependent patients did achieve transfusion independence with this
dosing strategy at a median followup of more than 1 year, no patient experienced a sustained
increase in hemoglobin of 2g/dL from baseline (59).
In addition to ongoing studies of JAK inhibitors, pomalidomide, and PEG-IFN-α-2a in
therapy of patients with MPNs, a number of studies continue to determine the efficacy of a
variety of histone deacetylase inhibitors (HDACi) in MPN patients. Mascarenhas et al.
presented the final results of a phase I study of the pan-HDACi LBH589 (panobinostat) in
MF patients at the 2011 ASH meeting (60). 18 patients were enrolled at 3 different dose
levels including 5 patients who have received > 6 months of therapy. Interestingly, several
patients experienced near CR results with extended therapy. DeAngelo et al. also presented
findings demonstrating that treatment with panobinostat reduces in vivo JAK2 levels,
JAK2V617F allele burden, JAK-STAT signaling, and inflammatory cytokine levels in
patients treated on a separate clinical trial of panobinostat (61). Based on these trials, a phase
II trial of LBH589 is underway with 25mg po TIW as the recommended dose. In addition to
the study of LBH589 in MF, Rambaldi et al. presented the results of a phase II study of the
HDACi givinostat plus hydroxyurea (HU) for HU-resistant PV patients (61). This study
revealed that the combination of givinostat plus HU is well tolerated and ~50% of patients
with HU-resistant disease achieved a PR or CR with combination of HU plus givinostat.
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Finally, in addition to the above studies on pharmaceutical agents in the therapy of MPN
patients, the results of a recently completed prospective study of allogeneic stem cell
transplantation in MF were presented at the 2011 ASH meeting. This study, conducted by
the MPD-Research Consortium, utilized a reduced-intensity conditioning regimen consisting
of fludarabine and melphalan (62). Gradt-versus host disease prophylaxis was with
tacrolimus and methotrexate. In addition, patients undergoing unrelated donor
transplantation or those with mismatched donor also received ATG. The initial results from
this study suggest that this conditioning regimen followed by transplant from a sibling donor
was very effective while MF patients undergoing unrelated stem cell transplants had a high-
rate of transplant-related mortality (53% of such treated patients died from causes related to
transplant).
Conclusions
BCR-ABL1-negative MPN are characterized by recurrent mutations that activate the JAK-
STAT pathway (mutations in JAK2, MPL, and LNK), dysregulate DNA cytosine
methylation/demethylation (TET2, DNMT3A), or alter post-translational modifications of
histones (EZH2, SUZ12, EED, JARID2). The systematic evaluation of these genetic
alterations in genetically-engineered mouse models has continued to inform our
understanding of MPN pathogenesis and HSC biology. In addition, these mutant molecules
may prove useful as drug targets or biomarkers for either predicting prognosis or monitoring
treatment response. More recent data regarding cytokines and parameters that quantify host
immune response suggest their additional value in disease prognostication.
Currently an increasing range of therapies is being investigated in MPN patients including
multiple early phase and phase III trials of a variety of JAK inhibitors, pomalidomide,
HDACi, and allogeneic stem cell transplantation with reduced-intensity conditioning (Table
II). Data from the ongoing trials of ruxolitinib, pacritinib, SAR302503, and CYT387 will be
critical in determining the safety of these drugs, their efficacy compared with best
alternative conventional therapies, and the unique clinical properties of each compound.
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Table II
Current Therapies Under Investigation for the Treatment of the Myeloproliferative Neoplasms (MPNs)
Presented at the 2011 American Society of Hematology Annual Meeting and/or Published in 2011
Class of therapya Compound Studyb Trial designc Results/commentd
JAK inhibitors
Ruxolitinib
COMFORT-I,
double- blind
placebo controlled
trial in MF patients
[13].
Data from 309 patients
reported, benefit over
placebo in reducing
spleen volume and
improving Total
Symptom Score at 24
weeks.
Potential beneficial effect on survival
compared with placebo in MF but
more extended follow-up will be
needed. Conflicting reports on
survival and safety of ruxolitinib
from retrospective follow-up of
phase I/II trial.
COMFORT-II,
randomized open-
label phase III trial
compared with best
available therapy in
MF patients [14].
Data from 219 patients
reported, 2:1
randomization, benefit
over placebo in reducing
spleen volume and
improving quality of life
metrics.
Data on effect of ruxolitinib at
reducing JAK2V617F allele burden
are not clear from initial results of
COMORT-I and –II.
SAR302503 Phase I for MF
patients [15].
28 patients treated in
dose-escalation cohort
and 31 at maximum
tolerated dose (680 mg
daily).
Significant decrease in spleen and
JAK2V617F allele burden with
minimal toxicities.
CYT387 Phase I/II for MF
patients [16].
Multicenter study with
single and twice-daily
doses investigated.
Substantial activity in reducing
spleen size, improving constitutional
symptoms, and improving anemia.
Thromobocytopenia most significant
side effect (16% subjects).
Pacritinib Phase II trial in MF
patients [17].
Data from 34 patients
reported. Drug
administered on a once
daily dose.
Once daily dose has minimal
myelosuppression and alleviates
splenomegaly and constitutional
symptoms. GI toxicity appears to be
main side effect thus far.
HDACi
Panobinostat Phase I trial in MF
patients [18].
Eighteen patients at 3
different dose levels,
several patients have
experienced near CR.
Phase II trial in MF is now underway
with 25 mg po TIW.
Givinostat + hydroxyurea Phase II for
hydroxyurea-
resistant PV patients
[19].
Forty-four patients with
JAK2V617 PV enrolled.
~50% patients achieved a PR or CR
based on ELN guidelines.
PEG-IFN-a2a Phase II trial for
patients with high-
risk PV [20].
Forty patients treated
with median follow of
77.4 months.
94% had a sustained hematological
response, including 82% with CR,
after 6.4 years median follow-up.
28% achieved complete molecular
response. 29% were able to stop peg-
IFNa- 2a and sustained
hematological response without
further therapy after a median time of
>28 months.
Pomalildomide
Phase I/II trial in
MF patients [21].
Doses ranging from 0.5
to 2 mg in 83 patients.
Improvement in anemia occurred at
median of 2.3 months and durable
for median of 16.5 months.
Phase II trial in MF
patients [22].
0.5 mg dose studied in
28 patients.
A proportion of patients achieved
transfusion-independence but none
with sustained increase in
hemoglobin >2 g /dL.
Allogeneic
hematopoietic stem
cell transplantation
Prospective study of
allogeneic transplant
with reduced
intensity
Thirty-two patients
received allogeneic
transplant from related
donor and 34 from an
unrelated donor.
Transplantation from a sibling donor
was very effective while transplants
from unrelated donors had a very
high-rate (53%) of transplant-related
mortality.
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Class of therapya Compound Studyb Trial designc Results/commentd
conditioning in MF
patients [23].
a
HDACi- histone deacetylase inhibitors.
b
ET—essential thrombocytosis; MF—myelofibrosis; PV—polycythemia vera.
cCR—complete remission; PR-partial remission.
d
ELN: European Leukemia Net; GI: gastrointestinal.
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